The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Official Title: First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer
Study ID: NCT04382898
Brief Summary: Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of BNT112 cancer vaccine (BNT112) monotherapy or in combination with cemiplimab in patients with metastatic castration resistant prostate cancer (mCRPC: Part 1 and Part 2 Arms 1A and 1B) and in patients with high-risk, localized prostate cancer (LPC). As of February 2023, the trial will be only recruiting LPC patients and no longer mCRPC patients.
Detailed Description: * BNT112 consists of messenger ribonucleic acid (mRNA \[or RNA\]) targeting 5 antigens expressed in de novo and metastatic prostate cancer that are separately complexed with liposomes to form serum-stable RNA lipoplexes (RNA-LPX). * The RNA molecules are immune-pharmacologically optimized for high stability, translational efficiency and presentation on major histocompatibility complex (MHC) class I and II molecules. The vaccine is intended for intravenous (IV) bolus injection. * The RNA-LPX cancer vaccine induces activation of both the adaptive immune system (vaccine antigen-specific CD8+/CD4+ T cell) as well as the innate immune system (TLR7 agonism of single-stranded RNA). The physiology of efficient induction, expansion and differentiation of antigen-specific T cells is associated with programmed death receptor-1 (PD-1) upregulation on these T cells. Thus, the cancer vaccine is expected to have a synergistic mechanism of action with anti-PD-1. * In summary, the mechanism of action of BNT112 both in monotherapy and in combination with anti-PD-1 immune checkpoint inhibitor cemiplimab, together with carefully selected and refined clinical setting presents a unique opportunity for patients with different stages of prostate cancer.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
The University of Arizona Cancer Center, Tucson, Arizona, United States
University of Miami Hospital & Clinics /Sylvester Comprehensive Cancer Center, Miami, Florida, United States
University of Pittsburgh Cancer Inst., Pittsburgh, Pennsylvania, United States
Urology San Antonio P.A., San Antonio, Texas, United States
University of Virginia Cancer Center, Charlottesville, Virginia, United States
Universitätsklinikum Bonn, Bonn, , Germany
Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, , Germany
Universitätsklinikum Münster, Münster, , Germany
Studienpraxis Urologie, Nürtingen, , Germany
Urologische Klinik Planegg, Planegg, , Germany
Universitätsklinikum Tübingen, Tübingen, , Germany
Magyar Honvédség Egészségügyi Központ (MH EK Honvédkórház), Budapest, , Hungary
Semmelweis Egyetem, Belgyógyászati Klinika, Budapest, , Hungary
Onkológiai Klinika, Debrecen, , Hungary
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Nyíregyháza, , Hungary
Szent Borbála Kórház, Tatabánya, , Hungary
Cancer Research UK Cambridge Centre, Cambridge, , United Kingdom
Velindre Cancer Centre (VCC), Cardiff, , United Kingdom
University of Glasgow, Beatson WoS Cancer Centre, Glasgow, , United Kingdom
University College London Hospitals, London, , United Kingdom
The Royal Marsden Hospital, London, , United Kingdom
University Hospital Southampton - Southampton General Hospital, Southampton, , United Kingdom
Name: BioNTech Responsible Person
Affiliation: BioNTech SE
Role: STUDY_DIRECTOR